NBTX ▼ -1.6% - Nanobiotix S.A. $NBTX - NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer Nanobiotix shares fell 1.6% today following the company's announcement of complete Phase 1 results for its JNJ-1900 (NBTXR3) candidate in inoperable, recurrent non-small cell lung cancer. The market's modest decline suggests investors may have found the trial readout underwhelming relative to expectations, though the headline provides no detail on the specific efficacy or safety data that drove the reaction. 14-SEP-2026 02:00 AM ET